Patent SG-11201808633R-A (SG)
Title: Anti-human vista antibodies and use thereof
Inventor: SNYDER LINDA
IPC: A61K38/16
Filed: 2017-04-14
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101111111101110101101101111101111011111 International Bureau 0.. .1 j ..... ..or::,„, (10) International Publication Number (43) International Publication Date WO 2017/181109 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: ROTHSTEIN, Jay [US/US]; 18 Elm Street, Norwich, A61K 38/16 (2006.01) C07K 14/705 (2006.01) Vermont 05055 (US). PECHENICK, Dov [US/US]; P.O. A61K 39/00 (2006.01) C07K 16/42 (2006.01) Box 333, New Hampton, New Hampshire 03256 (US). A61K 39/395 (2006.01) C07K 16/46 (2006.01) SNYDER, Linda [US/US]; 1795 Honeysuckle Lane, Pott- (21) International Application Number: sdown, Pennsylvania 19465 (US). POWERS, Gordon PCT/US2017/027765 [US/US]; 9 Lloyd Avenue, Malvern, Pennsylvania 19355 (US). (22) International Filing Date: (74) Agents: TESKIN, Robin, L. et al.; LECLAIR RYAN, 14 April 2017 (14.04.2017) P.C., Intellectual Property Department, 2318 Mill Road, (25) Filing Language: English Suite 1100, Alexandria, Virginia 22314 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 62/323,193 15 April 2016 (15.04.2016) US BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 62/343,355 31 May 2016 (31.05.2016) US DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, 62/363,929 19 July 2016 (19.07.2016) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 62/363,931 19 July 2016 (19.07.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 62/363,917 19 July 2016 (19.07.2016) US MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 62/364,073 19 July 2016 (19.07.2016) US NL NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 62/363,925 19 July 2016 (19.07.2016) US RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 62/365,085 21 July 2016 (21.07.2016) US TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 62/365,102 21 July 2016 (21.07.2016) US ZA, ZM, ZW. US 62/365,081 21 July 2016 (21.07.2016) 62/365,166 21 July 2016 (21.07.2016) US (84) Designated States (unless otherwise indicated, for every US kind of regional protection available): ARIPO (BW, GH, 62/365,087 21 July 2016 (21.07.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/372,362 9 August 2016 (09.08.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, = 62/385,627 9 September 2016 (09.09.2016) 62/385,805 9 September 2016 (09.09.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/385,871 9 September 2016 (09.09.2016) 62/385,888 9 September 2016 (09.09.2016) US LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 62/385,893 9 September 2016 (09.09.2016) US SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, US GW, KM, ML, MR, NE, SN, TD, TG). 62/385,785 9 September 2016 (09.09.2016) US Published: US 62/406,632 11 October 2016 (11.10.2016) 62/425,184 22 November 2016 (22.11.2016) PCT/US17/027800 14 April 2017 (14.04.2017) US — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (72) Inventors; and claims and to be republished in the event of receipt of Applicants MOLLOY, Michael 11 Marsten (71) : [US/US]; Lane, Unit 35, Enfield, New Hampshire 03748 (US). amendments (Rule 48.2(h)) THEREOF (54) Title: ANTI-HUMAN VISTA ANTIBODIES AND USE 1E 1111 1-1 C:r C:i Figure 1. In vitro and in vivo screening assays can be used to identify suppressive VISTA mAb. 11 A) Purified T cells were plated on top of anti-CD3 in the presence of the indicated mAb for 72 hours. Proliferation was measured by H 3 incorporation. Il GC Il ---- (57) : The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These ant - .' agonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and L ' ..::::; thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic N VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody O fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.